Posted by Michael Wonder on 18 Dec 2023
GC Biopharma announces US FDA approval for Alyglo (immune globulin intravenous, human-stwk) 10% liquid for adults with primary humoral immunodeficiency
18 December 2023 - - GC Biopharma today announces that the US FDA has approved Alyglo (immune globulin intravenous, human-stwk) 10% liquid for the treatment of adult patients aged 17 years and older with primary humoral immunodeficiency.
The Alyglo pivotal Phase 3 clinical study followed FDA guidance for the treatment of patients with primary humoral immunodeficiency.
